Deciphering the CNS anti-depressant, antioxidant and cytotoxic profiling of methanol and aqueous extracts of Trametes versicolor and molecular interactions of its phenolic compounds.

The present study sought to evaluate the central nervous system (CNS) depressant, antioxidant, and cytotoxicity activity of methanol and aqueous extract of Trametes versicolor (METV and AETV). The CNS activity was assessed by the open field, hole-cross, forced swimming, thiopental sodium-induced sleeping time, hole-board, and rotarod tests in Swiss albino mice. For both extracts, a substantial decrease in locomotion was observed in open field and hole-cross tests. In addition, the molecular docking study has been implemented through Maestro V11.1. The higher dose of METV (400 mg/kg) and the lower dose of AETV (200 mg/kg) exhibited a significant decrease in immobility time in forced swimming test and increased prolongation of sleep in thiopental sodium-induced sleeping time test, respectively. In contrast, a moderate finding was observed for the hole-board and rotarod tests. Additionally, a significant DPPH scavenging assay and a high toxicity effect in brine shrimp lethality assay were observed. Besides, five phenolic compounds, namely baicalin, quercetin, catechin, p-hydroxybenzoic acid, and quinic acid, were used for the molecular docking study, whereas catechin demonstrated the highest binding affinity towards the targets. The findings conclude that the T. versicolor could be an alternative source for CNS anti-depressant and antioxidant activity.

Wild mushrooms showed analgesic and cytotoxic properties along with phytoconstituent's binding affinity to COX-1, COX-2 and cytochrome P450 2C9.

This study was designed to evaluate the cytotoxic and analgesic potential of methanol extracts of five wild mushrooms available in the University of Chittagong, Bangladesh. The acetic acid-induced writhing method was used for the analgesic activity, while cytotoxicity was tested using brine shrimp lethality bioassay. In silico molecular docking and ADME/T study have been employed by using Schrodinger v11.1, BIOVIA Discovery Studio 2020 and online tool (AdmeSAR) respectively. The methanol extracts of Daldinia concentrica, Trametes lactinea, Fomitopsis cajanderi and Daedaleopsis confragosa exhibited a significant (p < 0.001) decrease in the number of writhing when compared to the control group. Except for Lentinus squarrosulus at 200 mg/kg body weight, the remaining mushroom extracts showed equal to or above 50 % inhibition of writhing. Daldinia concentrica showed the lowest LC50 values with 0.63 µg/mL, while Daedaleopsis confragosa showed the highest LC50 values of 2.33 µg/mL, indicating decisive cytotoxic action all mushrooms extracts. Considering the secondary metabolites, daldinan A and fomlactone A were found the most promising myco-compounds in analgesic and cytotoxic molecular docking studies. Besides, all the selected metabolites meet the rule of Lipinski's drug-likeliness. These results concluded that each mushroom extracts except Lentinus squarrosulus possess a potential analgesic. All the mushroom extracts embrace a promising cytotoxic activity that may guide the progress of a new drug.

Corrigendum to "Chemical profiles, pharmacological properties, and in silico studies provide new insights on Cycas pectinata" [Heliyon 6 (6), (June 2020) Article e04061].

[This corrects the article DOI: 10.1016/j.heliyon.2020.e04061.].

Chemical profiles, pharmacological properties, and in silico studies provide new insights on Cycas pectinata.

The current study aimed to qualitatively and quantitatively determine the phytochemical components of Cycas pectinata methanol extract (MECP), along with its antioxidant, anti-inflammatory, thrombolytic, locomotor, anxiolytic, analgesic, and antidiarrheal activities. The in vitro antioxidant activity was evaluated by DPPH scavenging assay and the total phenol and total flavonoid contents, while the anti-inflammatory activity was evaluated by a protein denaturation assay. The in vivo locomotor effects were examined using the open field test and hole-cross test. The anxiolytic effect was examined using the elevated plus maze (EPM) test, hole-board test (HBT), and light-dark test (LDT), while the analgesic activity was investigated using the acetic acid-induced writhing test. The antidiarrheal effect was evaluated by castor oil-induced diarrhea and gastrointestinal motility. Ten bioactive compounds were selected on the basis of their biological activities and further investigated using in silico molecular docking simulation to correlate with the identified pharmacological properties. Additionally, the ADME properties of the compounds were evaluated according to their drug-likeness profile. MECP had a maximum total phenol content of 209.85 ± 3.40 gallic acid equivalents/g extract and a total flavonoid content of 105.17 ± 3.45 quercetin equivalents/g extract, with an IC50 value of 631.44 µg/mL. MECP (62.5-500 µg/mL) elicited 20.96-38.12% decreased protein denaturation compared to diclofenac sodium (65.40-83.50%), while a 35.72% (P < 0.001) clot lysis activity was observed for the 10 mg/mL concentration. MECP induced a dose-dependent reduction in locomotor activity, with a significant anxiolytic effect. In the analgesic test, MECP (200, 400 mg/kg) showed a 45.12% and 58.82% inhibition in analgesia, and the 400 mg/kg dose elicited a 27.5% inhibition in intestinal motility. These findings suggest that MECP might be effective in treating antioxidant, anti-inflammatory, and neuropharmacological defects, but this requires further study.